Marel
Total Consideration
$4.40B
Purchase-Price Allocation
Goodwill
$2.32B
Intangibles
$1.16B
Assets Acquired
$402.2M
Pro-Forma Combined Entity
Revenue
$3.80B
Net Income
+$11.7M
JBT Marel Corporation — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Cash-Flow Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$-1
Book Value Per Share
$86
Free Cash Flow Per Share
$5
Cash Per Share
$3
Revenue Per Share
$73
OCF Per Share
$7
Return on Equity
-1.7%
Return on Assets
-0.9%
Return on Invested Capital
3.4%
Debt to Equity
0.33
Current Ratio
0.98
Quick Ratio
0.58
Asset Turnover
0.65
Days Sales Outstanding
42.56
Days Payables Outstanding
38.80
Days Inventory On Hand
95.37
Cash Conversion Cycle
99.13
R&D / Revenue
3.1%
SBC / Revenue
0.6%
Capex / Revenue
2.7%
Working Capital
$-39M
Net Current Asset Value
$1.58B
Invested Capital
$5.93B
OCF / Net Income
-6.77
FCF / Net Income
-4.71
Accruals Ratio (Sloan)
-4.8%
Net Debt
$1.71B
Net Debt / EBITDA
3.76
Interest Coverage
1.66
Cash Coverage
2.99
Dividend Coverage
16.35
Capex Coverage
3.30
Tangible Common Equity
$-1.09B
TCE / Total Assets
-13.3%
Goodwill / Total Assets
41.9%
NOPAT
$150M
Cash ROIC
5.5%
WC / Revenue
-1.0%
Capex / D&A
0.39
Reinvestment Rate
836.0%
Total Payout Ratio
-41.4%
Asset Growth vs Revenue Growth
18.6%
Revenue 5Y CAGR
17.1%
EPS 5Y CAGR
-7.9%
FCF 5Y CAGR
1.8%
EBITDA 5Y CAGR
14.2%
Book Value 5Y CAGR
46.0%
Stock Price (FY-end)
$151
Market Cap
$7.83B
P/E Ratio
47.75
P/S Ratio
2.06
P/B Ratio
1.75
P/TB Ratio
9.39
P/OCF Ratio
22.91
P/FCF Ratio
32.88
Enterprise Value
$9.54B
EV / EBITDA
20.95
EV / Sales
2.51
EV / FCF
40.08
FCF Yield
3.0%
Dividend Yield
0.3%
Shareholder Yield
-0.0%
Buyback Yield
0.0%
R&D Yield
1.5%
Capex Yield
1.3%
Dividend Per Share
$0
DPS YoY Growth
-1.2%
Operating Leverage
0.49
Graham Number
$53
Shares Variation (YoY)
61.5%
Beta (5Y)
1.23
Cost of Equity
10.6%
Cost of Debt (after tax)
4.8%
WACC
9.5%
ROIC - WACC Spread
-6.1%
52W High
$156
52W Low
$91
Trailing Return 1Y
17.7%
Trailing Return 5Y
30.0%
F-Score (Piotroski)
3.00
M-Score (Beneish)
—
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
EPS — Consensus vs Actual
Revenue — Consensus vs Actual
Beat / Miss vs Estimate
Stock Price on Earnings Dates
JBT Marel Corporation — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 3.00% | 2.00% | 2.00% | 2.00% | -1.00% | 15.00% |
| Foreign Rate Differential | 2.00% | 4.00% | 3.00% | 2.00% | 5.00% | — |
| Other Adjustments | 2.00% | 2.00% | -5.00% | -2.00% | 1.00% | 2.00% |
| R&D Tax Credits | 5.00% | 4.00% | 7.00% | 5.00% | 8.00% | -8.00% |
| Valuation Allowance Change | 0.00% | 0.00% | -2.00% | 0.00% | 1.00% | 0.00% |
| Tax Law Change | 0.00% | 4.00% | 0.00% | 0.00% | — | — |
| Effective Tax Rate | 25.00% | 23.00% | 14.00% | 15.00% | 11.00% | 21.00% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $36.7M | $27.0M | $16.2M | $23.5M | $10.7M | −$13.1M |
| Income Taxes Paid (Cash) | — | — | — | — | — | $68.7M |
JBT Marel Corporation — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
JBT Marel Corporation — RestructuringNEW
Per-category restructuring disclosures sourced from us-gaap:RestructuringCostAndReserveAxis dimensional XBRL. Negative charges indicate reversals of prior accruals (a sign the original estimate was too aggressive — flattering current-period earnings).
As of 2025-12-31
| Category | Class | P&L Charge | Cash Paid | Reserve Balance |
|---|---|---|---|---|
| Employee Severance | Employee Severance | — | $14M | $16M |
| Other Restructuring | Other | — | $600.0K | — |